Statistics

Views

Abstract: 1294

PDF (English): 593

Cited-by

CrossRef: 20

  1. Karakasis P, Theofilis P, Patoulias D, Vlachakis PK, Antoniadis AP, Fragakis N. Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies. International Journal of Molecular Sciences. 2025;26(5):2196. doi: 10.3390/ijms26052196
  2. Grigoriou K, Karakasis P, Pamporis K, Theofilis P, Patoulias D, Karagiannidis E, et al. Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies. Current Issues in Molecular Biology. 2025;47(7):559. doi: 10.3390/cimb47070559
  3. Karakasis P, Theofilis P, Vlachakis PK, Korantzopoulos P, Patoulias D, Antoniadis AP, et al. Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets. International Journal of Molecular Sciences. 2024;26(1):209. doi: 10.3390/ijms26010209
  4. Karakasis P, Theofilis P, Milaras N, Vlachakis PK, Patoulias D, Karamitsos T, et al. Epigenetic Drivers of Atrial Fibrillation: Mechanisms, Biomarkers, and Therapeutic Targets. International Journal of Molecular Sciences. 2025;26(11):5253. doi: 10.3390/ijms26115253
  5. Astiawati T, Rohman MS, Wihastuti T, Sujuti H, Endharti AT, Sargowo D, et al. Efficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, and Galectin-3 Expression and Improving Echocardiography Parameters in Acute Myocardial Infarction: A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. Journal of Clinical Medicine. 2025;14(4):1347. doi: 10.3390/jcm14041347
  6. Voziki D, Dimakopoulos G, Stergiou I, Zografou I, Rizzo M, Liberopoulos EN, et al. The effects of SGLT2 inhibitors and GLP-1 receptor agonists on the triglyceride to HDL cholesterol ratio and the triglyceride-glucose index in patients with type 2 diabetes. Journal of Diabetes and its Complications. 2025;39(6):109044. doi: 10.1016/j.jdiacomp.2025.109044
  7. Zhang Y, Lin T, Fan S, Wu Y. Dapagliflozin Suppressed Cuproptosis and Myocardial Fibrosis in Myocardial Infarction Through HIF-1α/TGF-β Pathway. Current Medical Science. 2025;45(4):831. doi: 10.1007/s11596-025-00076-6
  8. Koc AS, Cetin AE, Icen YK, Sumbul HE, Ugurlu M, Izlimek UC, et al. Carotid Intima–Media Thickness Is Associated with Long-Term Mortality in Patients with Non-ST Segment Elevation Myocardial Infarction. Journal of Clinical Medicine. 2025;14(13):4461. doi: 10.3390/jcm14134461
  9. Karakasis P, Patoulias D, Theofilis P, Fragakis N. Cardiovascular risk, meet the twins: Optimizing cardiometabolic care with SGLT2i and GLP-1RA combination therapy. International Journal of Cardiology. 2025;432:133272. doi: 10.1016/j.ijcard.2025.133272
  10. Karakasis P, Theofilis P, Patoulias D, Vlachakis PK, Pamporis K, Sagris M, et al. Sodium–Glucose Cotransporter 2 Inhibitors in Aortic Stenosis: Toward a Comprehensive Cardiometabolic Approach. International Journal of Molecular Sciences. 2025;26(10):4494. doi: 10.3390/ijms26104494
  11. McIntyre RS, Kwan AT. Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. Expert Opinion on Drug Safety. 2024;:1. doi: 10.1080/14740338.2024.2430306
  12. Karakasis P, Patoulias D, Giannakoulas G, Sagris M, Theofilis P, Fragakis N, et al. Effect of Glucagon-like Peptide-1 Receptor Agonism on Aortic Valve Stenosis Risk: A Mendelian Randomization Analysis. Journal of Clinical Medicine. 2024;13(21):6411. doi: 10.3390/jcm13216411
  13. Bertaina M, Galluzzo A, Carbonaro C, Marzulli A, Calcagnile C, Sbarra P, et al. SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives. Future Cardiology. 2025;21(7):515. doi: 10.1080/14796678.2025.2503666
  14. Karakasis P, Theofilis P, Vlachakis PK, Grigoriou K, Patoulias D, Antoniadis AP, et al. Reprogramming Atherosclerosis: Precision Drug Delivery, Nanomedicine, and Immune-Targeted Therapies for Cardiovascular Risk Reduction. Pharmaceutics. 2025;17(8):1028. doi: 10.3390/pharmaceutics17081028
  15. Karakasis P, Theofilis P, Vlachakis PK, Apostolos A, Milaras N, Ktenopoulos N, et al. SGLT2 inhibitors and cardiac fibrosis: A comprehensive review. Current Problems in Cardiology. 2025;50(10):103149. doi: 10.1016/j.cpcardiol.2025.103149
  16. Taroza S, Burkauskas J, Podlipskytė A, Kažukauskienė N, Mickuvienė N. Associations of Free and Reverse Triiodothyronine with Long-Term All-Cause Mortality After Acute Ischemic Stroke and Acute Myocardial Infarction. Journal of Clinical Medicine. 2025;14(5):1563. doi: 10.3390/jcm14051563
  17. Piccirillo F, Lanciotti M, Nusca A, Frau L, Spanò A, Liporace P, et al. Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes. International Journal of Molecular Sciences. 2025;26(5):2103. doi: 10.3390/ijms26052103
  18. Karakasis P, Sagris M, Patoulias D, Koufakis T, Theofilis P, Klisic A, et al. Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?. Biomedicines. 2024;12(11):2503. doi: 10.3390/biomedicines12112503
  19. Karakasis P, Theofilis P, Lefkou E, Antoniadis AP, Patoulias D, Korantzopoulos P, et al. Clonal Hematopoiesis of Indeterminate Potential and Atrial Fibrillation: Insights into Pathophysiology and Clinical Implications. International Journal of Molecular Sciences. 2025;26(6):2739. doi: 10.3390/ijms26062739
  20. Karakasis P, Theofilis P, Vlachakis PK, Ktenopoulos N, Patoulias D, Antoniadis AP, et al. Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts. Journal of Clinical Medicine. 2025;14(9):3250. doi: 10.3390/jcm14093250

Dimensions

Article Metrics

Metrics Loading ...

PlumX